Papers
1
Total Citations
62
H-Index
1
About
Runmei Li is a leading clinical oncologist whose research focuses on innovative neoadjuvant therapies for esophageal squamous cell carcinoma (ESCC), one of the most aggressive and treatment-refractory malignancies. Dr. Li’s major contribution is the design and execution of the Keystone-001 trial, a prospective, single-arm, phase-II study that investigates the safety and efficacy of combining pembrolizumab (an immune checkpoint inhibitor) with paclitaxel and cisplatin as neoadjuvant therapy for patients with locally advanced, resectable stage III ESCC. This protocol, published in 2022, has already garnered 62 citations, underscoring its significance in reshaping perioperative treatment paradigms. By integrating immunotherapy with chemotherapy before surgery, Dr. Li’s work aims to improve pathological complete response rates and long-term survival outcomes in a population where over 50% of global cases occur in China. This pioneering approach addresses a critical unmet need, offering a potential new standard for downstaging tumors prior to resection. Dr. Li’s research is highly impactful for oncologists and translational scientists seeking to optimize multimodal strategies for ESCC, bridging the gap between clinical trial design and real-world application in high-incidence regions.
Research Focus
Key Achievements
Top Papers
- 1